Galera Therapeutics Stock News

Galera Therapeutics (NASDAQ:GRTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Monday, Zacks.com reports. The brokerage currently has a $1.75 target price on the stock. Zacks Investment Researchs target price points to a potential upside of 32.58% from the companys previous close. []

Galera Therapeutics, Inc. (NASDAQ:GRTX) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 645,000 shares, a decline of 57.6% from the October 31st total of 1,520,000 shares. Based on an average daily volume of 2,770,000 shares, the days-to-cover ratio is currently 0.2 days. []

Galera Therapeutics Inc. (NASDAQ:GRTX) has seen 1.14 million shares traded in the last trading session. The company, currently valued at $39.84M, closed the last trade at $1.47 per share which meant it lost -$0.03 on the day or -2.00% during that session. The GRTX stock price is -783.67% off its 52-week high price of $12.99 Galera Therapeutics Inc. (GRTX) Is Becoming Less Appealing To Investors After A -2.00% Fall Read More »

Galera Therapeutics (NASDAQ:GRTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Thursday, Zacks.com reports. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The companys product candidate []

Zacks Investment Research lowered shares of Galera Therapeutics (NASDAQ:GRTX) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. []

Marshall Wace LLP lifted its holdings in Galera Therapeutics, Inc. (NASDAQ:GRTX) by 115.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 116,508 shares of the companys stock after acquiring an additional 62,394 shares during the period. Marshall Wace LLP owned []

Galera Therapeutics, Inc. (GRTX) with the stream of -3.23% also noticed, India Motus GI Holdings, Inc. (MOTS) encountered a rapid change of -1.06% in the last hour of Monday’s trading … The post Now Is The Time To Reconsider: Galera Therapeutics, Inc. (NASDAQ:GRTX), Motus GI Holdings, Inc. (NASDAQ:MOTS) appeared first on Stocks Equity .

Zacks Investment Research upgraded shares of Galera Therapeutics (NASDAQ:GRTX) from a hold rating to a buy rating in a research report report published on Friday, Zacks.com reports. The brokerage currently has $1.75 price objective on the stock. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing []

Galera Therapeutics, Inc. (NASDAQ:GRTX) has been given a consensus rating of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average […]

Zacks Investment Research lowered shares of Galera Therapeutics (NASDAQ:GRTX) from a buy rating to a hold rating in a research report released on Thursday, Zacks.com reports. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The companys product []

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November.

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop

Galera Therapeutics, Inc. (GRTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision

Shares of Galera Therapeutics Inc (NASDAQ: GRTX) tanked 73% on Tuesday after the company said its Avasopasem trial did not meet the primary endpoint. Avasopasem does not ‘significantly' reduce the i

MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop